Updated Jul 16, 2026 · Last SEC filing 2026-07-15
Rapport Therapeutics, Inc. (RAPP) has filed 16 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-15. 3 Form 8-K material event filings were reported by RAPP in the last 90 days. 6 Form 144 notices of proposed sale were filed for RAPP stock. InsiderAlpha tracks every RAPP SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0002012593 |
| Form 4 filings (90d) | 16 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 6 |
| Latest Form 4 filing | 2026-07-15 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer | S — Open-market sale [10b5-1] | 5.5K | $39.72 | $218K | SEC | |
| Ceesay Abraham | Chief Executive Officer | S — Open-market sale [10b5-1] | 2.7K | $40.57 | $111K | SEC | |
| Gault Cheryl | Chief Operating Officer | S — Open-market sale | 3.8K | $41.39 | $157K | SEC | |
| Gault Cheryl | Chief Operating Officer | S — Open-market sale | 1.0K | $43.15 | $43K | SEC | |
| Gault Cheryl | Chief Operating Officer | S — Open-market sale | 1.9K | $40.09 | $76K | SEC | |
| Gault Cheryl | Chief Operating Officer | S — Open-market sale | 3.3K | $42.17 | $140K | SEC | |
| Ceesay Abraham | Chief Executive Officer | S — Open-market sale | 7.3K | $39.77 | $292K | SEC | |
| Ceesay Abraham | Chief Executive Officer | S — Open-market sale | 876 | $40.34 | $35K | SEC | |
| Third Rock Ventures V, L.P. | Insider | S — Open-market sale | 18.6K | $40.05 | $744K | SEC | |
| Third Rock Ventures V, L.P. | Insider | S — Open-market sale | 133.6K | $40.24 | $5.38M | SEC | |
| Third Rock Ventures V, L.P. | Insider | S — Open-market sale | 5.0K | $40.31 | $202K | SEC | |
| Third Rock Ventures V, L.P. | Insider | S — Open-market sale | 271.5K | $40.12 | $10.89M | SEC | |
| Yeleswaram Krishnaswamy | Chief Development Officer | S — Open-market sale | 20.2K | $39.99 | $809K | SEC | |
| Third Rock Ventures V, L.P. | Insider | S — Open-market sale | 426.0K | $40.32 | $17.18M | SEC | |
| Yeleswaram Krishnaswamy | Chief Development Officer | S — Open-market sale [10b5-1] | 10.2K | $35.08 | $358K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Rapport Therapeutics, Inc. (RAPP). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Third Rock Ventures V, L.P. | 5 | $34.39M |
| Gault Cheryl | 4 | $416K |
| Ceesay Abraham | 4 | $656K |
| HEALY JAMES | 1 | — |
| Sanchez Ramiro | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in RAPP insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live RAPP dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.